Data from the Phase II trial saw three of the seven patients dosed with CAN-2409 surviving for more than 35 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback